Gustafsson and his team summarize the most recent results pertaining to the function of a nuclear receptor called estrogen receptor beta, or ERbeta, the biological and medical importance of which Gustafsson and his associates discovered in 1995.
The group found that this regulatory molecule prevents what is called epithelial-to-mesenchymal transition, or EMT, in the prostate gland. EMT is believed to have an essential role in prostate tumor development. ERbeta also has a growth-suppressive effect in colon cancer cells.
All of this, added to new insights gained by the researchers regarding ERbeta's interaction with certain genetic materials, suggests that this molecule is potentially an interesting pharmaceutical target in many diseases, including cancer.
A second research by Gustafsson and his group was "Both liver-X receptor (LXR) isoforms control energy expenditure by regulating Brown Adipose Tissue activity". The research shows that two specific nuclear receptors – LXRalfa and LXRbeta – act in such a way as to indicate they have a crucial role in regulating energy homeostasis, which is important to maintain the stability of normal biological states during adjustments to environmental changes. Gustafsson suggests, that these molecules should be considered as targets in pharmaceutical intervention against obesity.
Both studies were performed in collaboration with Gustafsson's colleagues from the Karolinska Institute in Sweden, where he continues his duties as a member of the Center for Biotechnology at Huddinge University Hospital at the Karolinska Institute. He also holds an appointment as an adjunct professor at Baylor College of Medicine in Houston.
MEDICA.de; Source: University of Houston